How can breakthrough technology serve the emerging markets?
In January 2010 Johan Van Hoof was appointed Global Therapeutic Area Head for Infectious Diseases & Vaccines, Pharmaceuticals Group, JnJ. As of June 2011, Johan took additional responsibilities, as COO Crucell, the Vaccine Company acquired by JnJ in February 2011. In this role he oversees Development and Manufacturing as Crucell. Entering the field of vaccines, J&J aims to broaden its leadership position in the infectious disease area to include prevention through vaccination, which today is the most cost-effective health intervention.
At the 12th annual World Vaccine Congress we will welcome Dr van Hoof, who will discuss how using breakthrough technology to allow for lower costs of goods reaching the emerging markets.
Can the vaccine industry remain at the forefront of innovation and keep prices at a global competitive level at the same time?
All this and much more will be discussed on April 11th 2012.
Get your questions ready!
Have a look at the Congress program here.
Ensure you join us at the event at the best possible ticket price by booking your place before the 27th January – register here.